Singapore markets closed

Precision BioSciences, Inc. (DTIL)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
1.4000-0.0100 (-0.71%)
At close: 01:00PM EST
1.4700 +0.07 (+5.00%)
After hours: 02:29PM EST
Full screen
Trade prices are not sourced from all markets
Previous close1.4100
Open1.4000
Bid1.4000 x 1400
Ask1.4100 x 900
Day's range1.3900 - 1.4599
52-week range1.1100 - 9.4100
Volume300,082
Avg. volume749,025
Market cap155.343M
Beta (5Y monthly)1.49
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • Business Wire

    Precision BioSciences Announces Change to its Board of Directors

    DURHAM, N.C., November 10, 2022--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS®-based ex vivo allogeneic CAR T and in vivo gene editing therapies, today announced that Dr. Raymond Schinazi is stepping down from the company’s Board of Directors and will continue as a member of the company’s SAB, lending his deep expertise in antiviral drug discovery and development.

  • Business Wire

    Precision BioSciences Reports Third Quarter 2022 Financial Results and Provides Business Update

    DURHAM, N.C., November 08, 2022--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS®-based ex vivo allogeneic CAR T and in vivo gene editing therapies, today announced financial results for the third quarter ended September 30, 2022 and provided a business update.

  • Business Wire

    Precision BioSciences Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

    DURHAM, N.C., November 04, 2022--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS®-based ex vivo allogeneic CAR T and in vivo gene editing therapies, today announced that, on November 2, 2022, the Compensation Committee of Precision’s Board of Directors approved the grant of inducement awards to new employees under the Precision BioSciences, Inc. 2021 Employment Inducement Incentive Award Plan ("Inducement Award Plan"). The inducement awards cons